interventional-pulmonology
(3)
CSA Medical, Inc.
CSA Medical is a Lexington, Massachusetts medical device company that develops spray cryotherapy technology for the lungs. Its flagship RejuvenAir System delivers a metered dose of -196°C liquid nitrogen through a bronchoscope to destroy the damaged, mucus-producing cells that drive chronic bronchitis in COPD patients, while preserving the underlying tissue matrix so healthy airway cells can regrow. Backed by roughly $161M in total funding including a $53M Series D in 2024, the company submitted its FDA PMA in January 2026 following a successful pivotal SPRAY-CB trial.
Interscope, Inc.
Interscope, Inc. is a Northbridge, Massachusetts medical device company that develops the EndoRotor, a flexible, powered endoscopic resection system that dissects, resects, and collects tissue in the gastrointestinal tract without thermal energy. Founded in 2011, the company created the first flexible microdebrider designed for the digestive tract and holds the first and only FDA marketing authorization for Direct Endoscopic Necrosectomy (DEN) in walled-off pancreatic necrosis. Interscope sells to interventional gastroenterologists and hospitals, and distributes the EndoRotor system through a partnership with Micro-Tech Endoscopy.
Wendelin Maners
Wendelin Maners is the President and CEO of CSA Medical, the Lexington, Massachusetts medical-device company behind the RejuvenAir System, a liquid-nitrogen cryospray technology delivered by bronchoscope. A finance-trained dealmaker who spent years buying and licensing emerging technologies for Boston Scientific, Maners moved from the deal table to the operating chair, taking the top job at CSA Medical in December 2019 and steering the company through an oversubscribed $53 million Series D and a fully enrolled pivotal trial on the road to FDA approval.